<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">56235</article-id><article-id pub-id-type="doi">10.7554/eLife.56235</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>The identification of dual protective agents against cisplatin-induced oto-and nephrotoxicity using the zebrafish model</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-176121"><name><surname>Wertman</surname><given-names>Jaime N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6029-3376</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178007"><name><surname>Melong</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178008"><name><surname>Stoyek</surname><given-names>Matthew R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178009"><name><surname>Piccolo</surname><given-names>Olivia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178010"><name><surname>Langley</surname><given-names>Stewart</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178011"><name><surname>Orr</surname><given-names>Benno</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178012"><name><surname>Steele</surname><given-names>Shelby L</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-178047"><name><surname>Razaghi</surname><given-names>Babak</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-178048"><name><surname>Berman</surname><given-names>Jason N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4053-6067</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Microbiology &amp; Immunology</institution>, <institution>Dalhousie University</institution>, <addr-line><named-content content-type="city">Halifax</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><institution content-type="dept">Pediatrics</institution>, <institution>Children's Hospital of Eastern Ontario Research Institute</institution>, <addr-line><named-content content-type="city">Ottawa</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><institution content-type="dept">Department of Physiology &amp; Biophysics</institution>, <institution>Dalhousie University</institution>, <addr-line><named-content content-type="city">Halifax</named-content></addr-line>, <country>Canada</country></aff><aff id="aff4"><institution content-type="dept">Pediatrics</institution>, <institution>IWK Health Centre</institution>, <addr-line><named-content content-type="city">Halifax</named-content></addr-line>, <country>Canada</country></aff><aff id="aff5"><institution content-type="dept">Department of Molecular Genetics</institution>, <institution>University of Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff6"><institution content-type="dept">Drug Development</institution>, <institution>Appili Therapeutics</institution>, <addr-line><named-content content-type="city">Halifax</named-content></addr-line>, <country>Canada</country></aff><aff id="aff7"><institution content-type="dept">Faculty of Dentistry</institution>, <institution>Dalhousie University</institution>, <addr-line><named-content content-type="city">Halifax</named-content></addr-line>, <country>Canada</country></aff><aff id="aff8"><institution content-type="dept">Hematology/Oncology</institution>, <institution>Children's Hospital of Eastern Ontario Research Institute</institution>, <addr-line><named-content content-type="city">Ottawa</named-content></addr-line>, <country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-149979"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing editor</role><aff><institution>Flinders Medical Centre</institution>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jberman@cheo.on.ca</email> (JB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>07</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e56235</elocation-id><history><date date-type="received"><day>21</day><month>02</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Wertman et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wertman et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-56235-v1.pdf"/><abstract><p>Dose-limiting toxicities for cisplatin administration, including ototoxicity and nephrotoxicity, impact the clinical utility of this effective chemotherapy agent and lead to lifelong complications, particularly in pediatric cancer survivors. Using a two-pronged drug screen employing the zebrafish lateral line as an <italic>in vivo</italic> readout for ototoxicity and kidney cell-based nephrotoxicity assay, we screened 1280 compounds and identified 22 that were both oto- and nephroprotective. Of these, dopamine and L-mimosine, a plant-based amino acid active in the dopamine pathway, were further investigated. Dopamine and L-mimosine protected the hair cells in the zebrafish otic vesicle from cisplatin-induced damage and preserved zebrafish larval glomerular filtration. Importantly, these compounds did not abrogate the cytotoxic effects of cisplatin on human cancer cells. This study provides insights into the mechanisms underlying cisplatin-induced oto- and nephrotoxicity and compelling preclinical evidence for the potential utility of dopamine and L-mimosine in the safer administration of cisplatin.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><funding-statement>No operating funds were directly associated with this work. Jaime Wertman was supported throughout the study by a Killam Predoctoral Award and an IWK Graduate Studentship.The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Shelby L Steele, Shelby L. Steele is affiliated with Appili Therapeutics Inc. The author has no financial interests to declare.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The use of zebrafish in this study was approved by, and carried out in accordance with, the policies of the Dalhousie University Committee on Laboratory Animals (Protocols #17-131 and #17-055).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The full list of hits from both the oto- and nephrotoxicity drug screens are available on Dryad, under the doi: 10.5061/dryad.zcrjdfn8n</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Jaime N Wertman</collab><collab>Nicole Melong</collab><collab>Matthew. R Stoyek</collab><collab>Olivia Piccolo</collab><collab>Stewart Langley</collab><collab>Benno Orr</collab><collab>Shelby L. Steele</collab><collab>Babak Razaghi</collab><collab>Jason N Berman</collab></person-group><year iso-8601-date="2020">2020</year><source>Results from: The identification of dual protective agents against cisplatin-induced oto-and nephrotoxicity using the zebrafish model</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.zcrjdfn8n">https://doi.org/10.5061/dryad.zcrjdfn8n</ext-link><comment>Dryad Digital Repository, 10.5061/dryad.zcrjdfn8n</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-56235-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>